Explore

Rapid Read Rapid Read
President Trump Appoints Kyle Diamantas as Acting FDA Chief Amid Policy Shifts

President Trump Appoints Kyle Diamantas as Acting FDA Chief Amid Policy Shifts

President Trump has appointed Kyle Diamantas as the acting commissioner of the Food and Drug Administration (FDA) following the resignation of Marty Makary. Diamantas, who previously led the FDA's Human Foods Program, is the first lawyer to head the agency, marking a significant departure from the traditional scientific or medical backgrounds of past commissioners. His appointment aligns with the Trump administration's 'Make America Healthy Again' initiative, which focuses on food policy changes. Diamantas' legal expertise is expected to play a crucial role in navigating the agency's regulatory landscape, particularly in areas such as food safety and chronic disease prevention.
Rapid Read Rapid Read
Biotech Executives Recommend Richard Pazdur as Next FDA Chief

Biotech Executives Recommend Richard Pazdur as Next FDA Chief

A group of over 100 biotech leaders has recommended Richard Pazdur to be the next head of the FDA, following the resignation of Marty Makary. In a letter to President Trump, the executives highlighted Pazdur's extensive experience and leadership qualities, citing his previous role as director of the FDA's Oncology Center of Excellence. The letter emphasized the need for stable leadership at the FDA to restore confidence in the agency's regulatory processes, which have been criticized for volatility and unpredictability. The recommendation comes amid concerns about the FDA's ability to maintain its leadership in biomedical innovation.
Reuters Reuters
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug

US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug

By Deena Beasley and Nancy Lapid May 14 (Reuters) - U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from Revolution Medicines while they await what they hope will be a speedy FDA approval.
AP News AP News
Supreme Court preserves access to widely used abortion pill, while lawsuit plays out

Supreme Court preserves access to widely used abortion pill, while lawsuit plays out

The Supreme Court has preserved women’s access to a drug used in the most common method of abortion, rejecting lower-court restrictions while a lawsuit continues
Reuters Reuters
Exclusive-FDA drug center head expected to leave after commissioner's exit, sources say

Exclusive-FDA drug center head expected to leave after commissioner's exit, sources say

By Yasmeen Abutaleb and Michael Erman WASHINGTON, May 15 (Reuters) - The acting head of the U.S.
Rapid Read Rapid Read
Supreme Court Decision Highlights Republican Divide on Abortion Policy

Supreme Court Decision Highlights Republican Divide on Abortion Policy

The Supreme Court recently ruled against Louisiana's attempt to end mail-in abortion pills, allowing women in states where abortion is illegal to continue accessing abortion medication remotely. This decision has exposed a significant divide within the Republican Party, particularly between President Trump and antiabortion advocates. President Trump has maintained that abortion should be a state issue, avoiding a nationwide ban, which contrasts with the demands of antiabortion groups who seek a federal prohibition. The ruling has intensified concerns among these groups that without a national ban, states with legal abortion will undermine those where it is banned, especially since the FDA allows abortion pills to be mailed. The decision has also sparked debate over state versus federal authority in regulating abortion access.
Rapid Read Rapid Read
Trump Administration to Withhold $1.3 Billion in Medicaid Payments from California Over Fraud Concerns

Trump Administration to Withhold $1.3 Billion in Medicaid Payments from California Over Fraud Concerns

The Trump administration has announced its decision to withhold $1.3 billion in federal Medicaid payments from the state of California. Vice President JD Vance stated that this action is due to California's failure to adequately address fraud within its public health insurance program. The administration has also initiated an audit of state-level Medicaid fraud control units, demanding proof of their effectiveness in combating fraud. This move is part of a broader effort by the administration to tackle misuse of public funds in federal programs, a task force for which was established by President Trump in March. The focus has primarily been on Democratic states, with previous actions including the halting of $259 million in payments to Minnesota following a welfare scandal.
AP News AP News
Trump's FDA chief is out after angering pharma CEOs, vaping lobbyists and anti-abortion activists

Trump's FDA chief is out after angering pharma CEOs, vaping lobbyists and anti-abortion activists

Marty Makary is resigning as President Donald Trump's Food and Drug Administration head
Rapid Read Rapid Read
President Trump Visits China Amid Rising Iran War Costs and FDA Leadership Change

President Trump Visits China Amid Rising Iran War Costs and FDA Leadership Change

President Trump has arrived in China as part of a diplomatic visit, marking a significant moment in U.S.-China relations. Concurrently, Pete Hegseth is under scrutiny on Capitol Hill regarding the escalating costs associated with the ongoing conflict in Iran. This development comes at a time when the U.S. is grappling with international military commitments and their financial implications. Additionally, the Food and Drug Administration (FDA) is experiencing a leadership change with the resignation of Commissioner Marty Makary. These events highlight a period of transition and challenge within U.S. political and administrative spheres.
Reuters Reuters
Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms

Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms

By Christy Santhosh May 13 (Reuters) - U.S. Food and Drug Administration Commissioner Dr. Marty Makary's departure comes as a positive move after a period of turmoil in the biotech sector, but until a permanent replacement is found, the industry could be under pressure, analysts and investors said.
AP News AP News
FDA chief's resignation widens a leadership gap at the nation's health department

FDA chief's resignation widens a leadership gap at the nation's health department

Dr. Marty Makary's resignation from his post atop the Food and Drug Administration is widening a leadership gap that already existed at the U.S. Department of Health and Human Services
Trendline Trendline
FDA Leadership Change: Makary Resigns, Diamantas Steps In

FDA Leadership Change: Makary Resigns, Diamantas Steps In

FDA Leadership Change: Makary Resigns, Diamantas Steps In